Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Vigabatrin add-on therapy for drug-resistant focal epilepsy.

< BACK TO ARCHIVE


2020 Jul 30


Cochrane Database Syst Rev


http://www.ncbi.nlm.nih.gov/pubmed/32730657?dopt=Abstract


7

Vigabatrin add-on therapy for drug-resistant focal epilepsy.

Authors

Vigabatrin add-on therapy for drug-resistant focal epilepsy.
Bresnahan R, Gianatsi M, Maguire MJ, Tudur Smith C, Marson AG
Cochrane Database Syst Rev. 2020 Jul 30; 7:CD007302.
PMID: 32730657.

Abstract

This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have focal epilepsy. Vigabatrin is an antiepileptic drug licensed for use in drug-resistant epilepsy.
Read This Paper